![Kin Yip Leung](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kin Yip Leung
Directeur/Membre du Conseil chez
NOVOCURE LIMITED
Fortune : 2 M $ au 31/05/2026
Profil
Mr. Kin Yip Leung is an Independent Director at NovoCure Ltd. He is on the Board of Directors at NovoCure Ltd. Mr. Leung was previously employed as an Independent Non-Executive Director by Pernix Therapeutics Holdings, Inc., an Independent Director by Albany Molecular Research, Inc., an EVP, President-Oncology & Diabetes Business by OSI Pharmaceuticals, Inc., a Group Vice President-Global Prescription Business by Pharmacia Corp., a Principal by Bristol Myers Squibb Co., and a Member by C-Change.
He also served on the board at BGH Medical Products and NanoMed Pharmaceuticals, Inc. He received his undergraduate degree from The University of Texas at Austin and a graduate degree from the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVOCURE LTD. 0,09 % | 03/06/2026 | 101 109 ( 0,09 % ) | 2 M $ | 31/05/2026 |
Postes actifs de Kin Yip Leung
| Sociétés | Poste | Début |
|---|---|---|
| NOVOCURE LIMITED | Directeur/Membre du Conseil | 05/08/2011 |
Anciens postes connus de Kin Yip Leung
| Sociétés | Poste | Fin |
|---|---|---|
| PERNIX THERAPEUTICS HOLDINGS INC | Directeur/Membre du Conseil | 09/05/2019 |
| ALBANY MOLECULAR RESEARCH, INC. | Directeur/Membre du Conseil | 04/02/2016 |
| DELCATH SYSTEMS, INC. | Président | 15/09/2014 |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2010 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Corporate Officer/Principal | 01/04/2003 |
Formation de Kin Yip Leung
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
77
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical drugs | Health Technology |
Curia Global, Inc.
 Curia Global, Inc. BiotechnologyHealth Technology Operates as a global contract research and manufacturing company that provides drug discovery, development & production services | Health Technology |
Delcath Systems, Inc.
 Delcath Systems, Inc. Medical SpecialtiesHealth Technology Develops and manufactures drugs for treatment of cancer | Health Technology |
NanoMed Pharmaceuticals, Inc.
 NanoMed Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic and diagnostic products | Commercial Services |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C-Change
 C-Change Other Consumer ServicesConsumer Services C-Change is a private company based in Washington, DC. C-Change was founded by Kevin Sharps, Lynn L. Davison. | Consumer Services |
NovoCure Ltd.
 NovoCure Ltd. Medical SpecialtiesHealth Technology Operates as a commercial-stage oncology company | Health Technology |
Pernix Therapeutics Holdings, Inc.
 Pernix Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
